PURPOSE Continuity of care is considered a core element of high-quality primary care, but its impact on mortality and health care costs is unclear. We aimed to determine the impact of continuity of care on mortality, costs, and health outcomes in patients with newly diagnosed cardiovascular risk factors. METHODSWe conducted a cohort study of a 3% nationwide random sample of Korean National Health Insurance enrollees. A total of 47,433 patients who had received new diagnoses of hypertension, diabetes, hypercholesterolemia, or their complications in 2003 or 2004 were included. We determined standard indices of continuity of care-most frequent provider continuity (MFPC), modified, modified continuity index (MMCI), and continuity of care index (COC)-and evaluated their association with study outcomes over 5 years of follow-up. Outcome measures included overall mortality, cardiovascular mortality, incident cardiovascular events, and health care costs. RESULTSThe multivariable-adjusted hazard ratios (HRs) for all-cause mortality, cardiovascular mortality, incident myocardial infarction, and incident ischemic stroke comparing participants with COC index below the median to those above the median were HR = 1.12 (95% CI, 1.04-1.21), 1.30 (1.13-1.50), 1.57 (1.28-1.95), and 1.44 (1.27-1.63), respectively. Similar findings were obtained for other indices of continuity of care. Lower continuity of care was also associated with increased inpatient and outpatient days and costs.CONCLUSIONS Lower indices of continuity of care in patients with newly diagnosed hypertension, diabetes, and hypercholesterolemia were associated with higher all-cause and cardiovascular mortality, cardiovascular events, and health care costs. Health care systems should be designed to support long-term trusting relationships between patients and physicians.

The aminoglycosides streptomycin, amikacin, and kanamycin and the cyclic polypeptide capreomycin are all widely used in second-line therapy for patients who develop multidrug-resistant tuberculosis. We have characterized a set of 106 clinical isolates of Mycobacterium tuberculosis using phenotypic drug susceptibility testing (DST) to determine the extent of resistance to each agent and cross-resistance between agents. These results were compared with polymorphisms in the DNA sequences of ribosome-associated genes previously implicated in resistance and with the clinical outcomes of subjects from whom these isolates were obtained. Thirty-six (34%) of these isolates displayed resistance to one or more of these agents, and the majority of these (20 of 36) showed cross-resistance to one or more agents. Most (33 of 36) of the resistant isolates showed polymorphisms in the 16S ribosome components RpsL and rrs. Three resistant strains (3 of 36) were identified that had no known polymorphisms in ribosomal constituents. For kanamycin and streptomycin, molecular DST significantly outperformed phenotypic DST using the absolute concentration method for predicting 4-month sputum conversion (likelihood ratios of 4.0 and 2.0, respectively) and was equivalent to phenotypic DST using the National Committee for Clinical Laboratory Standards (NCCLS)-approved agar proportion method for estimating MIC (likelihood ratio, 4.0). These results offer insight into mechanisms of resistance and crossresistance among these agents and suggest that the development of rapid molecular tests to distinguish polymorphisms would significantly enhance clinical utility of this important class of second-line antituberculosis drugs.Drug-resistant tuberculosis (TB) is an emerging issue in global TB control, with multidrug-resistant (MDR) and extensively drug-resistant (XDR) disease threatening to overwhelm existing initiatives (8). The difference between MDR TB (resistant to at least isoniazid [INH] and rifampin [RIF]) and XDR TB (MDR plus resistant to any fluoroquinolone and at least one of the injectable second-line drugs amikacin [AK], kanamycin [KM], and capreomycin [CM]) is often life or death for patients suffering from drug-resistant TB (7,14,15). Nonetheless, the diagnosis of MDR and XDR TB remains a lengthy, technically demanding laboratory procedure relying on culturing bacteria isolated from patient sputum on solid or liquid medium in the presence of individual drugs. To make matters worse, such highly resistant strains occasionally show growth differences in in vitro culture that may be related to fitness costs imposed by the mutations conferring resistance (9). These growth differences, and the complexity of in vitro assessment of drug resistance, result in laboratory determinations of XDR of questionable reliability (16). There is a growing movement toward molecular drug susceptibility testing using a variety of detection platforms that show robust performance for the firstline agents that define MDR TB (10).Molecular drug susceptibility t...

Mycolic acids are attractive diagnostic markers for tuberculosis (TB) infection because they are bacteria-derived, contain information about bacterial species, modulate host–pathogen interactions and are chemically inert. Here, we present a novel approach based on mass spectrometry. Quantification of specific precursor → fragment transitions of approximately 2000 individual mycolic acids (MAs) resulted in high analytical sensitivity and specificity. We next used this tool in a retrospective case–control study of patients with pulmonary TB with varying disease burdens from South Korea, Vietnam, Uganda and South Africa. MAs were extracted from small volume sputum (200 µl) and analysed without the requirement for derivatization. Infected patients (70, 19 of whom were HIV+) could be separated from controls (40, 20 of whom were HIV+) with a sensitivity and specificity of 94 and 93%, respectively. Furthermore, we quantified MA species in lung tissue of TB-infected mice and demonstrated effective clearance of MA levels following curative rifampicin treatment. Thus, our results demonstrate for the first time the feasibility and clinical relevance of direct detection of mycobacterial lipids as biomarkers of TB infection.

960, 1955, 2163b, 2165, 2996, 3192, 4052, and 4348) (h ‫؍‬ 0.98) that was able to differentiate most of the closely related strains was identified. These findings suggest that 24-locus-based MIRU-VNTR typing is a likely suitable alternative to RFLP to differentiate clinical isolates in this setting, which is dominated by M. tuberculosis Beijing strains. Within the study limits, our results also suggest that the problem of drug-resistant TB in the Republic of Korea may be largely due to acquired resistance as opposed to transmission.

The effects of hydroxyl quenching were examined on the photoluminescence properties of SnO 2 :Eu 3+ nanoparticles. High-quality SnO 2 :Eu 3+ nanoparticles were simply synthesized from SnCl 4 , EuCl 3 , and ethylene glycol. The photoluminescence spectra showed a reddish orange emission, which gradually increased with the calcination temperature in the range from 700 to 1000 °C. As the calcination temperature varied, the change of the OH -/O 2integrated-intensity ratios from X-ray photoelectron spectroscopy (XPS) was qualitatively consistent with that of the photoluminescence intensities. The samples obtained after the hydrothermal treatment and after reheating, respectively, exhibited a decline and recovery of their emission intensities, and this behavior with XPS confirmed the hydroxyl-quenching effect.

No abstract

MADRs are common during anti-tuberculosis chemotherapy in this population, occurring in more than one in six subjects. New and less toxic agents to treat drug-resistant TB are urgently needed.

The effects of carbon coating on ϳ9 nm SnO 2 particles were examined. The C-coated SnO 2 nanoparticles were synthesized from SnCl 4 , glucose, and ethylene glycol through a solvothermal method. Raman spectra indicated that the coated carbon was a disordered carbon. The C-coated SnO 2 nanoparticles showed superior cycling properties to the uncoated ones. Transmission electron microscopy after cycling confirmed that the nanoparticles were well dispersed without aggregation. The enhanced cycling property is believed to be attributed to the effective hindrance of nanoparticle growth by the core/shell structure of Sn/Li 2 O and carbon layer after phase separation during the first discharge.